Merck & Co.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
Bristol-Myers Squibb has appointed Christopher Boerner to replace Murdo Gordon, who left the company on August 3. Boerner will take on the positions of executive vice president and chief commercial officer, effective immediately.
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
Who made a splash in the biotech world this week? Here are some notable people.
Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).
The U.S. Food and Drug Administration (FDA) granted Merck & Co.’s Keytruda another approval, this one in combination with Alimta (pemetrexed) and platinum chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
Vantage Pharma published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital investment is up and mergers and acquisitions is down, while for the medical device company it’s the reverse.
Swiss Pharma giant Roche expanded its presence in China with the approval of its lung cancer drug, Alecesna. Roche said the medication was approved by the China National Drug Administration under a priority review.
Harbour BioMed signed an exclusive strategic partnership deal with Sichuan Kelun-Biotech Biopharmaceutical Co. to develop and commercialize an anti-PD-L1 antibody, A167, currently in Phase II development.
It’s a busy week on the U.S. Food and Drug Administration (FDA)’s calendar, although the agency got ahead of itself and approved three of the applications early. Here’s a look.
JOBS
IN THE PRESS